Quantisnow Logo
Dashboard

SEC Form SC 13D/A filed by Science 37 Holdings Inc. (Amendment)

$SNCE
Computer Software: Prepackaged Software
Technology
Get the next $SNCE alert in real time by email
SC 13D/A 1 d227421dsc13da.htm SC 13D/A SC 13D/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

SCIENCE 37 HOLDINGS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

808644108

(CUSIP Number)

Julia James

PPD, Inc.

929 North Front Street

Wilmington, North Carolina 28401

(910) 251-0081

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

With copies to:

William Brentani

Simpson Thacher & Bartlett LLP

2475 Hanover Street

Palo Alto, California 94304

(650) 251-5000

November 8, 2021

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

 

 

 

CUSIP NO. 808644108

 

  1.    

  Names of Reporting Persons.

 

  Pharmaceutical Product Development, LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☐

 

  3.  

  SEC Use Only

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

shares

 beneficially 

owned by

each

reporting

person

with:

      7.     

  Sole Voting Power

 

  17,379,797

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  17,379,797

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  17,379,797

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  15.2%

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

CUSIP NO. 808644108

 

  1.    

  Names of Reporting Persons.

 

  Wildcat Acquisition Holdings (UK) Limited

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☐

 

  3.  

  SEC Use Only

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  United Kingdom

Number of

shares

 beneficially 

owned by

each

reporting

person

with:

      7.     

  Sole Voting Power

 

  17,379,797

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  17,379,797

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  17,379,797

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  15.2%

14.  

  Type of Reporting Person (See Instructions)

 

  CO

CUSIP NO. 808644108

 

  1.    

  Names of Reporting Persons.

 

  Jaguar Holding Company II

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☐

 

  3.  

  SEC Use Only

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

shares

 beneficially 

owned by

each

reporting

person

with:

      7.     

  Sole Voting Power

 

  17,379,797

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  17,379,797

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  17,379,797

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  15.2%

14.  

  Type of Reporting Person (See Instructions)

 

  CO

CUSIP NO. 808644108

 

  1.    

  Names of Reporting Persons.

 

  Jaguar Holding Company I, LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☐

 

  3.  

  SEC Use Only

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

shares

 beneficially 

owned by

each

reporting

person

with:

      7.     

  Sole Voting Power

 

  17,379,797

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  17,379,797

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  17,379,797

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  15.2%

14.  

  Type of Reporting Person (See Instructions)

 

  OO

CUSIP NO. 808644108

 

  1.    

  Names of Reporting Persons.

 

  Eagle Holding Company II, LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☐

 

  3.  

  SEC Use Only

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

shares

 beneficially 

owned by

each

reporting

person

with:

      7.     

  Sole Voting Power

 

  17,379,797

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  17,379,797

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  17,379,797

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  15.2%

14.  

  Type of Reporting Person (See Instructions)

 

  OO

CUSIP NO. 808644108

 

  1.    

  Names of Reporting Persons.

 

  PPD, Inc.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☐

 

  3.  

  SEC Use Only

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

shares

 beneficially 

owned by

each

reporting

person

with:

      7.     

  Sole Voting Power

 

  17,379,797

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  17,379,797

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  17,379,797

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  15.2%

14.  

  Type of Reporting Person (See Instructions)

 

  CO

This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D relates to the common stock, par value $0.0001 per share (“Common Stock”), of Science 37 Holdings, Inc. (formerly known as LifeSci Acquisition II Corp.), a Delaware corporation (the “Issuer”), and amends and supplements the initial statement on Schedule 13D filed by the Reporting Persons on October 18, 2021 (the “Original Schedule 13D” and, as amended and supplemented by this Amendment No. 1, the “Schedule 13D”). This Amendment No. 1 is only being filed to correct the number and percentage of shares of Common Stock beneficially owned by the Reporting Persons following the Business Combination as reported in the Original Schedule 13D. There have been no transactions in the Common Stock by the Reporting Persons since the filing of the Original Schedule 13D, and information reported in the Original Schedule 13D remains in effect except to the extent that it is amended or superseded by information contained in this Amendment No. 1. Capitalized terms used but not defined in this Amendment No. 1 shall have the same meanings ascribed to them in the Original Schedule 13D.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Original Schedule 13D is hereby amended and restated as follows:

On October 6, 2021 (the “Closing Date”), in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 6, 2021 (the “Merger Agreement”), by and among LifeSci Acquisition II Corp. (“LSAQ”), LifeSci Acquisition II Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of LSAQ (“Merger Sub”) and Science 37, Inc., a Delaware corporation (“Science 37”), among other things, Merger Sub merged with and into Science 37 (the “Business Combination”) with Science 37 surviving the merger as a wholly-owned subsidiary of LSAQ. Following the Business Combination, LSAQ was renamed “Science 37 Holdings, Inc.” In exchange for their ownership of preferred stock of Science 37 prior to the Business Combination, Pharma LLC received 16,879,797 shares of Common Stock of the Issuer in accordance with the terms of the Merger Agreement.

Immediately prior to the closing of the Business Combination, Pharma LLC also purchased 500,000 shares of Common Stock in a private placement at a purchase price of $10.00 per share (the “PIPE Investment”). Pharma LLC’s payment of the purchase price in the PIPE Investment was funded through the working capital of Pharma LLC.

Item 5. Interest in Securities of the Issuer

Item 5(a)-(c) of the Original Schedule 13D is hereby amended and restated as follows:

The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 3 and 4 is incorporated by reference in its entirety into this Item 5.

(a), (b) The following disclosure assumes that there are 114,707,150 shares of Common Stock outstanding, as set forth in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 13, 2021.

Pursuant to Rule 13d-3 of the rules and regulations promulgated by the SEC pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Reporting Persons may be deemed to beneficially own an aggregate of 17,379,797 shares of Common Stock, representing approximately 15.2% of shares of Common Stock outstanding.

Any beneficial ownership of Common Stock by any of the persons listed on Schedule I is set forth on Schedule I of the Original Schedule 13D.

(c) Except as set forth in Item 3 of this Schedule 13D, none of the Reporting Persons, nor to its knowledge, any person listed on Schedule I of the Original Schedule 13D, has effected any transactions in Common Stock during the past 60 days.

Signatures

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: November 8, 2021

 

PPD, INC.
By:  

/s/ Julia James

Name: Julia James
Title: EVP, General Counsel and Secretary
EAGLE HOLDING COMPANY II, LLC
By:  

/s/ B. Judd Hartman

Name: B. Judd Hartman
Title: General Counsel and Secretary
JAGUAR HOLDING COMPANY I, LLC
By: Eagle Holding Company II, LLC, its Managing Member
By:  

/s/ B. Judd Hartman

Name: B. Judd Hartman
Title: General Counsel and Secretary
JAGUAR HOLDING COMPANY II
By:  

/s/ Julia James

Name: Julia James
Title: General Counsel and Secretary
WILDCAT ACQUISITION HOLDINGS (UK) LIMITED
By:  

/s/ B. Judd Hartman

Name: B. Judd Hartman
Title: Director
PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
By:  

/s/ Julia James

Name: Julia James
Title: EVP, General Counsel and Secretary

[Schedule 13D/A Signature Page]

Get the next $SNCE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SNCE

DatePrice TargetRatingAnalyst
11/1/2021$15.00Buy
Lake Street
11/1/2021$15.00Outperform
Robert W. Baird
11/1/2021Outperform
William Blair
11/1/2021$15.00Outperform
Baird
10/22/2021$14.00Outperform
Cowen & Co.
More analyst ratings

$SNCE
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

    MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing

    $SNCE
    Computer Software: Prepackaged Software
    Technology

  • Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

    MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, GSK. The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial

    $SNCE
    Computer Software: Prepackaged Software
    Technology

  • Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

    MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park. The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportunities for collaborative problem-solving and integrated solution delivery. Centralizing operations in one facility will enable Science 37 to deliver patient recruitment and study conduct support on behalf of clinical trial sponsors with greater consistency, speed, and quality

    $SNCE
    Computer Software: Prepackaged Software
    Technology

$SNCE
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SNCE
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SNCE
 SEC Filings

See more

$SNCE
 Leadership Updates

Live Leadership Updates

See more

  • Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

    MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing

    $SNCE
    Computer Software: Prepackaged Software
    Technology

  • Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity

    RESEARCH TRIANGLE PARK, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, announced today Erica Prowisor as SVP of Patient and Provider Networks to accelerate patient recruitment, ensure participant diversity and gain operational efficiencies. Erica has been forging new ground as a leader in patient recruitment for nearly 20 years, most notably with IQVIA where she was Global Head of Recruitment and Retention for more than three years and led the company's direct-to-patient recruitment and retention efforts. Prior to IQVIA, Erica spent 11 years with Acurian through the acquisition by PPD where she was Head of Enrollment Opera

    $SNCE
    Computer Software: Prepackaged Software
    Technology

  • Science 37 Adds New Head of Quality, Irena Lambridis

    RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance. Irena will be responsible for overseeing quality and compliance across all functions, including the Company's newly announced global Centers of Excellence in India, Pakistan, and Slovakia. This key appointment reflects Science 37's commitment to quality as it expands operations globally. Irena brings nearly two decades of experience in clinical research quality assurance, having held senior leadership positions at KCR and Novella Clinical (now IQVIA

    $SNCE
    Computer Software: Prepackaged Software
    Technology

$SNCE
 Financials

Live finance-specific insights

See more

  • Science 37 Reports Third Quarter 2023 Financial Results

    RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023. "Our third quarter results were highlighted by continued quarterly improvements in our key profitability metrics and cash burn rate," stated David Coman, Chief Executive Officer of Science 37. "We look forward to a strong finish to the year and positive momentum headed into 2024." Quarterly Financial Highlights Gross bookings were $17.9 million for the quarter ended September 30, 2023, a 50.6%

    $SNCE
    Computer Software: Prepackaged Software
    Technology

  • Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023

    RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™ today announced it will report third quarter 2023 financial results prior to the market open on Tuesday, November 7, 2023. The Science 37 management team will host a conference call to discuss these results on November 7, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using the Conference ID 13741458 or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the i

    $SNCE
    Computer Software: Prepackaged Software
    Technology

  • Science 37 Reports Second Quarter 2023 Financial Results

    RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended June 30, 2023. "The actions we have taken over the past nine months are leading to meaningful improvements as evidenced by our sequential quarterly results including growth in gross bookings and gross profit margins along with a reduction in cash burn," stated David Coman, Chief Executive Officer of Science 37. "We look forward to finishing the year strong and continuing to position the company for sustainable financial growth and shareholder value creation." Quarterly Financial

    $SNCE
    Computer Software: Prepackaged Software
    Technology

$SNCE
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more